Roviello G, et al. - Investigators examined 25 cases to estimate the prognostication of pain in the overall survival in males with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223. The histologically confirmed mCRPC cases were given 6 intravenous injections of radium-223 every 4 weeks. They adopted a visual analog scale (VAS) to assess the patients’ basal pain and observed 24% with VAS <4 suggesting the use of VAS as a prognostic of the survival of mCRPC.